Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer
Ravi A. Madan(National Cancer Institute), William L. Dahut(National Cancer Institute), Akira Yuno(National Institutes of Health), Cody J. Peer(National Institutes of Health), Guin Chun, Jennifer L. Marté(National Cancer Institute), Munjid Al Harthy(Sultan Qaboos University), Lisa M. Cordes(National Institutes of Health Clinical Center), Jane B. Trepel(National Institutes of Health), Amy Hankin(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Yusuke Tomita(Kumamoto University Hospital), Daniel P. Petrylak(Yale University), Fatima Karzai(National Institutes of Health), Joseph W. Kim(National Cancer Institute), Marc R. Theoret(United States Food and Drug Administration), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), William D. Figg(National Cancer Institute), Inger Rosner(Walter Reed National Military Medical Center), Anna Couvillon(National Institutes of Health), Sunmin Lee(Brigham and Women's Hospital), Helen Owens(National Institutes of Health), Min‐Jung Lee, Nancy A. Dawson(University of Maryland, Baltimore), Moniquea Williams(National Cancer Institute)
Cited by 13
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k